2022
DOI: 10.1016/j.vph.2022.106995
|View full text |Cite
|
Sign up to set email alerts
|

Challenges facing the clinical translation of cardioprotection: 35 years after the discovery of ischemic preconditioning

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(10 citation statements)
references
References 278 publications
0
7
0
Order By: Relevance
“…Ischemic preconditioning is considered the gold standard of cardioprotection ( Basalay et al, 2020 ). In remote preconditioning, brief episodes of I/R are administered to organs or tissues other than the heart and can be easily applied in a non-invasive way, e.g., using a blood pressure cuff on an arm or a leg ( Lang and Kim, 2022 ; Penna et al, 2022 ; Comità et al, 2023 ; Ferdinandy et al, 2023 ; Zhao et al, 2023 ). Another way to protect the heart against the consequences of I/R injury is pharmacological conditioning (i.e., volatile anesthetics, opioids or α 2 -adrenoceptor agonists), a concept that is based on the administration of specific drugs mimicking the effect of ischemic preconditioning ( Roth et al, 2021 ; Penna et al, 2022 ; Ferdinandy et al, 2023 ).…”
Section: Cardioprotective Role Of Endocannabinoids During Preconditio...mentioning
confidence: 99%
See 1 more Smart Citation
“…Ischemic preconditioning is considered the gold standard of cardioprotection ( Basalay et al, 2020 ). In remote preconditioning, brief episodes of I/R are administered to organs or tissues other than the heart and can be easily applied in a non-invasive way, e.g., using a blood pressure cuff on an arm or a leg ( Lang and Kim, 2022 ; Penna et al, 2022 ; Comità et al, 2023 ; Ferdinandy et al, 2023 ; Zhao et al, 2023 ). Another way to protect the heart against the consequences of I/R injury is pharmacological conditioning (i.e., volatile anesthetics, opioids or α 2 -adrenoceptor agonists), a concept that is based on the administration of specific drugs mimicking the effect of ischemic preconditioning ( Roth et al, 2021 ; Penna et al, 2022 ; Ferdinandy et al, 2023 ).…”
Section: Cardioprotective Role Of Endocannabinoids During Preconditio...mentioning
confidence: 99%
“…Controlled occlusions or pharmacological interventions activate a molecular self-defense program which delays the progression of infarction. The subsequent activation of multiple endogenous cardioprotective mechanisms including adenosine, protein kinase, calcium signalling, nitric oxide release, reduction in ROS but also the involvement of autacoids, hormones, neurotransmitters and cytokines lead to cardioprotection and reduce infarct size ( Penna et al, 2022 ; Heusch, 2023 ).…”
Section: Cardioprotective Role Of Endocannabinoids During Preconditio...mentioning
confidence: 99%
“…All of these pathways converge to the mitochondria, acting through the opening of the mitochondrial ATP-sensitive potassium channel (mKATP) and the mitochondrial permeability transition pore (mPTP). Reviewed below are important molecules involved in cardioprotection [ 3 5 ].
Fig.
…”
Section: Molecular Mechanisms Of Cardioprotectionmentioning
confidence: 99%
“…However, reduced infarct size and improved cardiac function have been observed after inhibition or deficiency of one of the components of the NLRP3 inflammasome or using several NLRP3 inhibitors and gene silencing [ 46 49 ]. Interestingly, the fact that ischemic preconditioning (IPreC) was ineffective in NLRP3-deficient mice suggests that NLRP3 may play a double role in the ischemia–reperfusion heart, being able to trigger protective signaling and participating in IPreC, but also able to concur with the progression of cardiac injury and promoting cardiomyocyte loss after ischemia–reperfusion [ 50 ]. Furthermore, more about the inflammasome-independent role of NLRP3 and inflammasome protective signaling in AMI is described in detail in another review article [ 51 , 52 ].…”
Section: Molecular Mechanisms Of Cardioprotectionmentioning
confidence: 99%
“…To solve the contradiction between the significant cardioprotective effect obtained by a single cardioprotective strategy in animal experiments and the failure of clinical translation is the original intention of the multi-target strategy. One of the common denominators of the shortcomings of multiple translational trials is that patients have other specific comorbidities in addition to the application of PCI (1,3,22,45,59,71,(78)(79)(80). Consequently, we hypothesize that the multi-target strategy for protecting myocardial IRI in the animal testing stage may be applied to specific comorbidities, exert a more substantial cardioprotective effect, and better guide clinical trials (81).…”
Section: Multi-target Strategies For Myocardial Ischemia-reperfusion ...mentioning
confidence: 99%